FR08C0039I2 - Composes azapolycycliques fusionnes avec un aryle - Google Patents

Composes azapolycycliques fusionnes avec un aryle

Info

Publication number
FR08C0039I2
FR08C0039I2 FR08C0039C FR08C0039C FR08C0039I2 FR 08C0039 I2 FR08C0039 I2 FR 08C0039I2 FR 08C0039 C FR08C0039 C FR 08C0039C FR 08C0039 C FR08C0039 C FR 08C0039C FR 08C0039 I2 FR08C0039 I2 FR 08C0039I2
Authority
FR
France
Prior art keywords
aryl
compounds fused
azapolycyclic compounds
azapolycyclic
fused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR08C0039C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22094096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR08C0039(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of FR08C0039I1 publication Critical patent/FR08C0039I1/fr
Application granted granted Critical
Publication of FR08C0039I2 publication Critical patent/FR08C0039I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/24—Camphidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
FR08C0039C 1997-12-31 2008-07-21 Composes azapolycycliques fusionnes avec un aryle Active FR08C0039I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7024597P 1997-12-31 1997-12-31
PCT/IB1998/001813 WO1999035131A1 (en) 1997-12-31 1998-11-13 Aryl fused azapolycyclic compounds

Publications (2)

Publication Number Publication Date
FR08C0039I1 FR08C0039I1 (sk) 2008-11-14
FR08C0039I2 true FR08C0039I2 (fr) 2009-12-18

Family

ID=22094096

Family Applications (1)

Application Number Title Priority Date Filing Date
FR08C0039C Active FR08C0039I2 (fr) 1997-12-31 2008-07-21 Composes azapolycycliques fusionnes avec un aryle

Country Status (52)

Country Link
US (6) US6410550B1 (sk)
EP (2) EP1659114A3 (sk)
JP (1) JP3550359B2 (sk)
KR (1) KR100408138B1 (sk)
CN (2) CN1324013C (sk)
AP (1) AP1170A (sk)
AR (1) AR017967A1 (sk)
AT (1) ATE386024T1 (sk)
AU (1) AU753389C (sk)
BG (1) BG65058B1 (sk)
BR (2) BR9816186B1 (sk)
CA (1) CA2316921C (sk)
CO (1) CO4810373A1 (sk)
CY (2) CY1107391T1 (sk)
CZ (1) CZ301925B6 (sk)
DE (2) DE122008000038I1 (sk)
DK (1) DK1044189T4 (sk)
DZ (1) DZ2697A1 (sk)
EA (1) EA003190B1 (sk)
EG (1) EG23816A (sk)
ES (1) ES2301210T5 (sk)
FR (1) FR08C0039I2 (sk)
GT (2) GT199800200A (sk)
HK (1) HK1031878A1 (sk)
HN (1) HN1998000177A (sk)
HR (2) HRP20000445B1 (sk)
HU (2) HU230297B1 (sk)
IL (2) IL136727A0 (sk)
IS (1) IS5514A (sk)
LU (1) LU91442I2 (sk)
MA (1) MA26589A1 (sk)
ME (1) ME00459B (sk)
MY (1) MY118163A (sk)
NL (1) NL300355I2 (sk)
NO (2) NO319115B1 (sk)
NZ (1) NZ504482A (sk)
OA (1) OA11428A (sk)
PA (1) PA8463901A1 (sk)
PE (1) PE20000053A1 (sk)
PL (1) PL209404B1 (sk)
PT (1) PT1044189E (sk)
RS (1) RS50069B (sk)
SA (1) SA99191123B1 (sk)
SG (1) SG102686A1 (sk)
SI (1) SI1044189T2 (sk)
SK (1) SK286886B6 (sk)
TN (1) TNSN98237A1 (sk)
TR (1) TR200001840T2 (sk)
TW (1) TW513412B (sk)
UA (1) UA66825C2 (sk)
WO (1) WO1999035131A1 (sk)
ZA (1) ZA9811911B (sk)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
DE122008000038I1 (de) * 1997-12-31 2008-11-13 Pfizer Prod Inc Arylkondensierte azapolycyclische derivate
DE60040293D1 (de) 1999-07-28 2008-10-30 Univ R Verwendung von nikotin in der angiogenese und der vaskulogenese
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20020010192A1 (en) * 2000-06-02 2002-01-24 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
KR100551183B1 (ko) * 2001-04-20 2006-02-13 화이자 프로덕츠 인크. 1,3-치환 인덴 및 아릴-융합 아자폴리시클릭 화합물의제조 방법
NZ528209A (en) 2001-05-14 2004-09-24 Pfizer Prod Inc The citrate salt of 5, 8, 14-triazatetracyclo (10.3.1.02,11.04.9)-hexadeca-2.(11),3,5,7,9-pentaene
PT1392307E (pt) * 2001-05-14 2005-11-30 Pfizer Prod Inc Sais tartarato de 5,8,14-triazatetraciclo-[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno
RU2004116311A (ru) 2001-11-29 2005-03-27 Пфайзер Продактс Инк. (Us) Сукцинатные соли 5,8,14-триазатетрацикло [10.3.1.02,11(04,9]гексадека- 2(11),3,5,7,9-пентаена и их фармацевтические композиции
ES2282492T3 (es) 2001-11-30 2007-10-16 Pfizer Products Inc. Composiciones farmaceuticas de liberacion controlada orales de 5,8,14-triazatetraciclo (10.3.1.0(2,11).0(4,9)-hexadeca-2(11)3,5,7,9-pentaeno.
RU2004116320A (ru) 2001-11-30 2005-10-10 Пфайзер Продактс Инк. (Us) Арилконденсированные азаполициклические соединения
US8143210B2 (en) * 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7320788B2 (en) * 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
ES2361993T5 (es) * 2002-02-14 2014-12-09 The Board Of Trustees Of The Leland Stanford Junior University Tratamiento con enzimas de productos alimenticios para celiaquía
US7265093B2 (en) * 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
AU2003234597A1 (en) * 2002-05-14 2003-12-02 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7462688B2 (en) * 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
US7202216B2 (en) * 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
EP1961737A1 (en) * 2002-11-20 2008-08-27 Pfizer Products Inc. Indan-1,3-carbodinitrile dervatives
EP1563300B1 (en) 2002-11-20 2012-04-18 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic method for celiac sprue
WO2004048318A1 (en) * 2002-11-25 2004-06-10 Pfizer Products Inc. Improved process for the preparation of 1,3-substituted indenes
WO2004063164A1 (en) * 2003-01-15 2004-07-29 Pfizer Products Inc. Process for the preparation of aryl fused polycyclic lactams
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
WO2004103372A1 (en) * 2003-05-20 2004-12-02 Pfizer Products Inc. Pharmaceutical compositions of varenicline
WO2004108725A1 (en) * 2003-06-04 2004-12-16 Pfizer Products Inc. Preparation of substituted quinoxalines from the dianline with 2,3-dihydroxy-1,4-dioxane
DE602004023299D1 (de) * 2003-07-21 2009-11-05 Pfizer Prod Inc Nikotin abhängigkeit reduzierende heteroaryl kondensierte azapolycyclische verbindungen
EP1648872A2 (en) * 2003-07-21 2006-04-26 Pfizer Products Inc. Aryl fused azapolycyclic compounds
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20050043406A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US7534426B2 (en) * 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
US7563864B2 (en) * 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
US7628985B2 (en) * 2004-04-26 2009-12-08 The Board Of Regents Of The Leland Stanford Junior University Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
WO2006006071A1 (en) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution of an aryl-fused azapolycyclic compound
US7766018B2 (en) 2004-09-30 2010-08-03 Smoke-Break, Inc. Device and composition for reducing the incidence of tobacco smoking
KR20070098942A (ko) * 2005-02-24 2007-10-05 화이자 프로덕츠 인코포레이티드 고순도의 치환된 퀴녹살린의 제조 방법
US20060211649A1 (en) * 2005-03-21 2006-09-21 Eric Marchewitz Use of cytisine for enhancing physical performance
WO2007076875A2 (en) * 2006-01-06 2007-07-12 Aarhus Universitet Compounds acting on the serotonin transporter
EP2004186A2 (en) * 2006-03-27 2008-12-24 Pfizer Products Inc. Varenicline standards and impurity controls
BRPI0710914A2 (pt) * 2006-04-24 2011-09-27 Pfizer Prod Inc forma de dosagem e método para o tratamento de dependência, adição e supressão de nicotina, em particular para uso na terapia para parar de fumar
WO2008028903A2 (en) 2006-09-04 2008-03-13 Neurosearch A/S Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
KR20090086071A (ko) * 2006-11-09 2009-08-10 화이자 프로덕츠 인코포레이티드 니코틴 중간체의 다형체
BRPI0808987A2 (pt) * 2007-03-16 2014-09-09 Univ Leland Stanford Junior Terapia combinatória de enzima para digestão de glúten dietético
WO2009034431A2 (en) 2007-09-10 2009-03-19 Pfizer Inc. Controlled-release dosage forms for varenicline
WO2009101185A2 (en) * 2008-02-15 2009-08-20 Medichem, S.A. A NEW POLYMORPHIC FORM OF A PYRAZINO[2,3-h][3] BENZAZEPINE DERIVATIVE
US20090215787A1 (en) * 2008-02-22 2009-08-27 Mai De Ltd. Preparations of new polymorphic forms of varenicline tartrate
JP2011516489A (ja) 2008-03-31 2011-05-26 ユニバーシティ・オブ・サウス・フロリダ 疾患誘発性運動失調症および非運動失調性平衡異常の治療法
CA2709774C (en) * 2008-05-22 2012-10-02 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318460A1 (en) * 2008-05-26 2009-12-24 Glenmark Amorphous varenicline tartrate and process for the preparation thereof
WO2009155403A2 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Processes for the preparation of varenicline and intermediates thereof
WO2010005643A1 (en) * 2008-07-10 2010-01-14 Teva Pharmaceutical Industries Ltd. Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
US8314235B2 (en) * 2008-09-01 2012-11-20 Actavis Group Ptc Ehf Process for preparing varenicline, varenicline intermediates, pharmaceutically acceptable salts thereof
EP2204369A1 (en) 2008-12-22 2010-07-07 Medichem, S.A. Process for preparing varenicline and intermediates for use therein
EP2396327A1 (en) 2009-02-11 2011-12-21 Sunovion Pharmaceuticals Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
US20120093887A1 (en) 2009-06-10 2012-04-19 Actavis Group Ptc Ehf Amorphous varenicline tartrate co-precipitates
EP2438054A1 (en) 2009-06-22 2012-04-11 Teva Pharmaceutical Industries Ltd. Solid states forms of varenicline salts and processes for preparation thereof
EP2475662A2 (en) * 2009-09-11 2012-07-18 Sunovion Pharmaceuticals Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
US20130101630A1 (en) 2010-03-09 2013-04-25 Actavis Group Ptc Ehf Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity
KR101109389B1 (ko) * 2010-04-30 2012-01-30 삼성전기주식회사 인쇄회로기판 및 그 제조방법
WO2011140431A1 (en) 2010-05-06 2011-11-10 Teva Pharmaceutical Industries Ltd. Varenicline salts and crystal forms thereof
US20120004239A1 (en) 2010-06-11 2012-01-05 Medichem, S.A. Process for Preparing Quinoxaline Derivatives
AU2012276651A1 (en) 2011-06-30 2014-02-06 Toray Industries, Inc. Antipruritic agent
ITMI20111413A1 (it) * 2011-07-28 2013-01-29 Dipharma Francis Srl Procedimento per la preparazione di vareniclina
ES2426517B1 (es) 2012-04-20 2014-05-14 Genetracer Biotech S.L Método para predecir la seguridad de un tratamiento farmacológico
ES2426838B1 (es) 2012-04-20 2014-05-07 Genetracer Biotech S.L Método para predecir el éxito en el abandono del consumo de tabaco en respuesta a un tratamiento farmacológico
CN103570502A (zh) * 2012-07-18 2014-02-12 上海科胜药物研发有限公司 一种伐伦克林中间体的制备方法
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
CN103992272B (zh) * 2014-06-09 2016-05-11 安徽省逸欣铭医药科技有限公司 一种盐酸喷他佐辛酯、其制备方法及其用途
KR20160126697A (ko) 2015-04-24 2016-11-02 한미정밀화학주식회사 신규 결정형의 바레니클린 옥살산 염 수화물, 이의 제조방법, 및 이를 포함하는 약학 조성물
KR20160143407A (ko) 2015-06-05 2016-12-14 한미정밀화학주식회사 신규한 바레니클린 뮤케이트 염, 이의 결정형 및 이의 제조방법
KR101724301B1 (ko) 2016-11-22 2017-04-10 주식회사 한서켐 바레니클린 살리실산염의 i형 결정 및 그 제조방법
CN106674194B (zh) * 2016-12-14 2019-03-05 山东省联合农药工业有限公司 一种结构新颖的烟碱类杀虫剂及其制备方法和用途
KR20180101268A (ko) 2017-03-03 2018-09-12 주식회사 씨티씨바이오 바레니클린 또는 이의 약학적으로 허용가능한 염의 포접 복합체를 포함하는 구강 투여용 제제
KR102463733B1 (ko) 2017-06-30 2022-11-04 한미약품 주식회사 함량 균일성 및 안정성이 향상된 바레니클린 옥살산염이 포함된 약제학적 조성물
WO2018154395A2 (en) 2018-06-11 2018-08-30 Alvogen Malta Operations (Row) Ltd Controlled release pharmaceutical composition of varenicline
KR20200034293A (ko) 2018-09-21 2020-03-31 한미약품 주식회사 제어 방출용 바레니클린 제제
EP4142734A1 (en) 2020-04-28 2023-03-08 Oyster Point Pharma, Inc. Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
CN113956255A (zh) * 2020-07-20 2022-01-21 威智医药有限公司 一种伐尼克兰中间体、伐尼克兰及其盐的制备方法
WO2022035434A1 (en) 2020-08-14 2022-02-17 Almatica Pharma Llc Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof
US11040983B1 (en) 2020-08-14 2021-06-22 Almatica Pharma Llc Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof
WO2022147189A1 (en) * 2020-12-30 2022-07-07 Antares Pharma, Inc. Varenicline prodrugs
WO2022222019A1 (en) * 2021-04-20 2022-10-27 Suzhou Fude Zhaofeng Biochemical Technology Co., Ltd Total synthesis of varenicline
CN113277993B (zh) * 2021-06-06 2023-07-21 湖南第一师范学院 一种Tafamidis及其衍生物的合成方法
WO2023275413A2 (en) 2021-12-23 2023-01-05 Medichem, S.A. Solid pharmaceutical formulations of varenicline
EP4241775A1 (en) 2022-03-11 2023-09-13 Par Pharmaceutical, Inc. Tablet comprising varenicline and process of preparation thereof
US11602537B2 (en) 2022-03-11 2023-03-14 Par Pharmaceutical, Inc. Varenicline compound and process of manufacture thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471503A (en) * 1967-05-05 1969-10-07 Mcneilab Inc 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
CH644116A5 (de) * 1980-08-21 1984-07-13 Hoffmann La Roche Imidazolderivate.
EP0853621A1 (en) † 1995-09-22 1998-07-22 Novo Nordisk A/S Novel substituted azacyclic or azabicyclic compounds
DE122008000038I1 (de) * 1997-12-31 2008-11-13 Pfizer Prod Inc Arylkondensierte azapolycyclische derivate
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
AU1918299A (en) * 1998-02-23 1999-09-06 Warner-Lambert Company Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
EP0955301A3 (en) * 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
PT1076650E (pt) * 1998-04-29 2004-05-31 Pfizer Prod Inc Compostos azapoliciclicos fundidos com arilo
JP4676062B2 (ja) * 1999-01-29 2011-04-27 アボット・ラボラトリーズ ニコチン性アセチルコリン受容体リガンドとしてのジアザ２環式誘導体
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
PT1392307E (pt) * 2001-05-14 2005-11-30 Pfizer Prod Inc Sais tartarato de 5,8,14-triazatetraciclo-[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno
NZ528209A (en) * 2001-05-14 2004-09-24 Pfizer Prod Inc The citrate salt of 5, 8, 14-triazatetracyclo (10.3.1.02,11.04.9)-hexadeca-2.(11),3,5,7,9-pentaene
RU2004116311A (ru) * 2001-11-29 2005-03-27 Пфайзер Продактс Инк. (Us) Сукцинатные соли 5,8,14-триазатетрацикло [10.3.1.02,11(04,9]гексадека- 2(11),3,5,7,9-пентаена и их фармацевтические композиции
RU2004116320A (ru) * 2001-11-30 2005-10-10 Пфайзер Продактс Инк. (Us) Арилконденсированные азаполициклические соединения
ES2282492T3 (es) * 2001-11-30 2007-10-16 Pfizer Products Inc. Composiciones farmaceuticas de liberacion controlada orales de 5,8,14-triazatetraciclo (10.3.1.0(2,11).0(4,9)-hexadeca-2(11)3,5,7,9-pentaeno.
EP1648872A2 (en) * 2003-07-21 2006-04-26 Pfizer Products Inc. Aryl fused azapolycyclic compounds

Also Published As

Publication number Publication date
LU91442I2 (fr) 2008-07-21
CZ20002438A3 (cs) 2002-11-13
KR20010033823A (ko) 2001-04-25
NO20003422D0 (no) 2000-06-30
DE69839131D1 (de) 2008-03-27
DE122008000038I1 (de) 2008-11-13
AP9801422A0 (en) 1998-12-31
MA26589A1 (fr) 2004-12-20
SK286886B6 (sk) 2009-07-06
HN1998000177A (es) 1999-02-09
CY2008013I2 (el) 2009-11-04
NL300355I2 (nl) 2008-11-03
BG104561A (en) 2001-01-31
CN1285821A (zh) 2001-02-28
DZ2697A1 (fr) 2003-03-29
NZ504482A (en) 2003-01-31
US6897310B2 (en) 2005-05-24
PA8463901A1 (es) 2000-09-29
ATE386024T1 (de) 2008-03-15
PL341824A1 (en) 2001-05-07
BR9814592B1 (pt) 2010-06-01
US20020132824A1 (en) 2002-09-19
BR9814592A (pt) 2000-10-17
NO20003422L (no) 2000-08-29
IL136727A (en) 2006-06-11
ES2301210T3 (es) 2008-06-16
ES2301210T5 (es) 2015-05-07
EA003190B1 (ru) 2003-02-27
NO319115B1 (no) 2005-06-20
HRP20050506A2 (en) 2006-03-31
DE69839131T3 (de) 2015-05-07
UA66825C2 (uk) 2004-06-15
SI1044189T2 (sl) 2015-05-29
BR9816186B1 (pt) 2009-01-13
SG102686A1 (en) 2004-03-26
US6410550B1 (en) 2002-06-25
OA11428A (en) 2004-05-03
NL300355I1 (nl) 2008-08-01
DE69839131T2 (de) 2009-02-05
HRP20000445B1 (en) 2009-04-30
CZ301925B6 (cs) 2010-08-04
RS50069B (sr) 2009-01-22
TW513412B (en) 2002-12-11
US20020072524A1 (en) 2002-06-13
NO2006016I2 (sk) 2008-10-20
KR100408138B1 (ko) 2003-12-01
CN1715280A (zh) 2006-01-04
EA200000592A1 (ru) 2000-12-25
EP1044189B1 (en) 2008-02-13
US6951938B2 (en) 2005-10-04
HU230297B1 (hu) 2015-12-28
ZA9811911B (en) 2000-06-29
IS5514A (is) 2000-05-26
AU753389B2 (en) 2002-10-17
HRP20000445A2 (en) 2001-04-30
HUP0100949A2 (hu) 2001-08-28
ME00459B (me) 2011-10-10
JP2002500218A (ja) 2002-01-08
CN1324013C (zh) 2007-07-04
EP1659114A2 (en) 2006-05-24
LU91442I9 (sk) 2018-12-31
TR200001840T2 (tr) 2000-12-21
US20020072525A1 (en) 2002-06-13
PE20000053A1 (es) 2000-02-07
WO1999035131A1 (en) 1999-07-15
MY118163A (en) 2004-09-30
CA2316921C (en) 2004-12-07
AU753389C (en) 2007-08-09
DK1044189T4 (en) 2015-03-30
CO4810373A1 (es) 1999-06-30
DK1044189T3 (da) 2008-05-13
NO2006016I1 (no) 2006-11-27
CY2008013I1 (el) 2009-11-04
SK9712000A3 (en) 2002-03-05
EG23816A (en) 2007-09-19
BG65058B1 (bg) 2007-01-31
AU9641698A (en) 1999-07-26
GT199800200AA (es) 2000-06-07
EP1659114A3 (en) 2007-01-17
SA99191123B1 (ar) 2006-10-02
HUS1600018I1 (hu) 2018-05-02
PL209404B1 (pl) 2011-08-31
YU40300A (sh) 2003-10-31
US20020111350A1 (en) 2002-08-15
AP1170A (en) 2003-06-30
CY1107391T1 (el) 2010-07-28
US6887884B2 (en) 2005-05-03
HK1031878A1 (en) 2001-06-29
US20070275973A1 (en) 2007-11-29
CA2316921A1 (en) 1999-07-15
SI1044189T1 (sl) 2008-06-30
TNSN98237A1 (fr) 2005-03-15
EP1044189B2 (en) 2015-02-25
AR017967A1 (es) 2001-10-24
FR08C0039I1 (sk) 2008-11-14
EP1044189A1 (en) 2000-10-18
IL136727A0 (en) 2001-06-14
JP3550359B2 (ja) 2004-08-04
HUP0100949A3 (en) 2002-12-28
PT1044189E (pt) 2008-04-22
GT199800200A (es) 2000-06-07

Similar Documents

Publication Publication Date Title
FR08C0039I2 (fr) Composes azapolycycliques fusionnes avec un aryle
DE69719705D1 (de) Tonerkassette
DE69822940D1 (de) Antistatische Thermoplastabmischung
DE69935516D1 (de) Antikörper mit verbesserter produzierbarkeit
DE69831198D1 (de) Tonervorratsbehälter
DE69835304D1 (de) Fluorierung mit Aminoschwefeltrifluoriden
MA26467A1 (fr) Composes inhibant les metalloproteases.
DE69720156D1 (de) Tonerkassette
DE69727900D1 (de) Tonerkassette
DE69724929D1 (de) Tonerkassette
MA26681A1 (fr) Composes pyrazine
IS5649A (is) Arýl sambrædd azapólýsýklísk efnasambönd
NO996354D0 (no) Periferisk virkende anti-pruritiske opiater
DE69817039D1 (de) Tonerkartusche
DE69720936D1 (de) Tonerkassette
DE1039709T1 (de) Empfänger
MA26587A1 (fr) Composes de triazine
DE69928527D1 (de) Farbtoner
MA24499A1 (fr) Nouveaux composes
DE69715988T2 (de) Tonerkartusche
DK0862197T3 (da) Sikringsstik
DE69815048D1 (de) Kopiergerät
DE59806187D1 (de) Entwicklerstation mit querförderung
GB9716101D0 (en) Fused heterocyclic compounds
NO970846D0 (no) Tilhenger med lokk